Lonza’s Synaffix has partnered with Qurient Therapeutics to develop dual-payload antibody-drug conjugates (ADCs) combining exatecan-based cytotoxics with a CDK7 inhibitor for solid tumors, aiming to enhance efficacy and overcome resistance. Separately, Akari Therapeutics reported promising preclinical data on PH1, an ADC payload targeting androgen receptor splice variants in prostate cancer. These developments highlight the growing sophistication and diversification of ADCs and immunotherapies directed at recalcitrant cancers, showcasing next-generation payloads and combination strategies to improve patient outcomes.